Comparison of Inspiratory Muscle Training and Volume-Oriented Incentive Spirometry on Respiratory Muscle Strength in Older Adults With Respiratory Muscle Weakness

A randomized controlled trial comparing POWERbreathe and Voldyne on respiratory muscle strength in older adults with respitatory muscle weakness

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20260219006

Enrollment

Registered

2026-02-19

Start date

2026-02-12

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Older Adults With Respiratory Muscle Weakness Respiratory Muscle Strength Muscle weakness Inspiratory Muscle Training Incentive Spirometry Aged Older adults

Interventions

IMT will be performed in 3 sets of 10 repetitions, twice a day, 5 days a week, for a total of 6 weeks. The training load will be set at 30-40 per cent of baseline maximal inspiratory pressure (MIP) du

Experimental Device,Active Comparator Device

Inspiratory Muscle Training (IMT) group,Volume-Oriented Incentive Spirometer (VIS) group

Eligibility

Sex/Gender

All

Age

65 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients aged 65 - 80 years who have respiratory muscle weakness (determined by MIP equal to or less than 83 cmH2O for men and 57 cmH2O for women), 2. Able to walk, 3. Good cognitive function (Mini-Cog test score of equal to or more than 3)

Exclusion criteria

Exclusion criteria: 1. Communication problems/Uncooperation, 2. Inability to measure pulmonary function for any reason 3. Malformation of the mouth or palate without correction, or a weak mouth 4. Absolute contraindications for pulmonary function test, inspiratory muscle training, or incentive spirometry as follows: unstable angina, recent myocardial infarction (within 4 weeks), significant chest or abdominal pain during breathing exercises, uncontrolled arrhythmias or severe hypertension, severe respiratory distress or acute respiratory failure, active hemoptysis, active pulmonary embolism or untreated/recent pneumothorax, recent eye surgery (e.g., retinal detachment), cardiac, thoracic, abdominal, or brain surgery (within 4 weeks)

Design outcomes

Primary

Measure	Time frame
Inspiratory muscle strength at baseline and 6 weeks after end of the intervention Maximal Inspiratory pressure (MIP)	—

Secondary

Measure	Time frame
Expiratory muscle strength at baseline and 6 weeks after end of the intervention Maximal Expiratory pressure (MEP),Pulmonary function at baseline and 6 weeks after end of the intervention Force Vital Capacity (FVC), Forced Expiratory Volume in the first second (FEV1), and Peak Expiratory Flow Rate (PEFR),Dyspnea at baseline and 6 weeks after end of the intervention Rate of perceived breathless (RPB),Patient preference at 6 weeks after end of the intervention Visual Analogue Scale (VAS)	—

Measure

Time frame

Expiratory muscle strength at baseline and 6 weeks after end of the intervention Maximal Expiratory pressure (MEP),Pulmonary function at baseline and 6 weeks after end of the intervention Force Vital Capacity (FVC), Forced Expiratory Volume in the first second (FEV1), and Peak Expiratory Flow Rate (PEFR),Dyspnea at baseline and 6 weeks after end of the intervention Rate of perceived breathless (RPB),Patient preference at 6 weeks after end of the intervention Visual Analogue Scale (VAS)

—

Countries

Thailand

Contacts

Public ContactRattaya Pornpotisatid

Faculty of medicine Ramathibodi hospital, Mahidol University

rattaya.ppt@gmail.com022011154

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 10, 2026